Great West Life Assurance Co. Can Increases Stake in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)
Great West Life Assurance Co. Can grew its stake in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 7.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 48,184 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,260 shares during the period. Great West Life Assurance Co. Can’s holdings in AMAG Pharmaceuticals were worth $620,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also bought and sold shares of the stock. Robeco Institutional Asset Management B.V. raised its holdings in shares of AMAG Pharmaceuticals by 6.4% in the 1st quarter. Robeco Institutional Asset Management B.V. now owns 1,304,639 shares of the specialty pharmaceutical company’s stock worth $16,803,000 after acquiring an additional 79,007 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of AMAG Pharmaceuticals by 8.7% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 697,652 shares of the specialty pharmaceutical company’s stock worth $10,597,000 after acquiring an additional 56,122 shares during the last quarter. Royce & Associates LP raised its holdings in shares of AMAG Pharmaceuticals by 686.7% in the 4th quarter. Royce & Associates LP now owns 666,904 shares of the specialty pharmaceutical company’s stock worth $10,130,000 after acquiring an additional 582,135 shares during the last quarter. Great Point Partners LLC acquired a new stake in shares of AMAG Pharmaceuticals in the 4th quarter worth about $10,097,000. Finally, Spark Investment Management LLC raised its holdings in shares of AMAG Pharmaceuticals by 211.1% in the 1st quarter. Spark Investment Management LLC now owns 371,100 shares of the specialty pharmaceutical company’s stock worth $4,779,000 after acquiring an additional 251,800 shares during the last quarter.
In related news, insider Elizabeth Scott Bolgiano bought 5,000 shares of AMAG Pharmaceuticals stock in a transaction dated Thursday, May 9th. The stock was purchased at an average cost of $10.93 per share, with a total value of $54,650.00. Following the transaction, the insider now directly owns 74,847 shares of the company’s stock, valued at $818,077.71. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Julie Krop bought 10,000 shares of AMAG Pharmaceuticals stock in a transaction dated Tuesday, May 28th. The shares were bought at an average cost of $9.91 per share, with a total value of $99,100.00. Following the completion of the transaction, the insider now directly owns 81,399 shares in the company, valued at $806,664.09. The disclosure for this purchase can be found here. Insiders acquired a total of 25,000 shares of company stock valued at $260,750 over the last ninety days. 4.90% of the stock is currently owned by insiders.
Shares of AMAG stock opened at $8.99 on Friday. AMAG Pharmaceuticals, Inc. has a 52-week low of $8.85 and a 52-week high of $26.10. The company has a quick ratio of 2.13, a current ratio of 2.30 and a debt-to-equity ratio of 0.44.
AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported ($3.32) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($2.77). AMAG Pharmaceuticals had a negative return on equity of 26.33% and a negative net margin of 30.90%. The firm had revenue of $75.80 million during the quarter, compared to the consensus estimate of $90.13 million. During the same period in the previous year, the company posted ($1.59) earnings per share. The company’s revenue for the quarter was down 35.4% on a year-over-year basis. Research analysts anticipate that AMAG Pharmaceuticals, Inc. will post -5.72 EPS for the current fiscal year.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Featured Story: What is the return on assets formula?
Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.